Get the Stockscreener App
3.57
0.56%
0.02
After Hours:
3.60
0.03
+0.84%
Cervomed Inc stock is traded at $3.57, with a volume of 761.16K.
It is up +0.56% in the last 24 hours and up +21.43% over the past month.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$3.55
Open:
$3.55
24h Volume:
761.16K
Relative Volume:
0.15
Market Cap:
$33.05M
Revenue:
$2.09M
Net Income/Loss:
$-30.04M
P/E Ratio:
-1.0922
EPS:
-3.2685
Net Cash Flow:
$-27.57M
1W Performance:
+13.33%
1M Performance:
+21.43%
6M Performance:
-52.68%
1Y Performance:
-36.81%
1-Day Range:
$3.435
$3.63
1-Week Range:
$3.05
$3.9298
52-Week Range:
$2.13
$13.13
Cervomed Inc Stock (CRVO) Company Profile
Name
Cervomed Inc
Sector
Industry
Phone
(617) 744-4400
Address
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
3.57 | 28.70M | 2.09M | -30.04M | -27.57M | -3.2685 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Dec-17-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-11-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-11-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-10-24 | Downgrade | D. Boral Capital | Buy → Hold |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Dec-05-24 | Initiated | H.C. Wainwright | Buy |
| Sep-18-24 | Initiated | Chardan Capital Markets | Buy |
| Jul-26-24 | Initiated | Morgan Stanley | Overweight |
| Feb-15-24 | Initiated | Canaccord Genuity | Buy |
| Nov-17-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-21-18 | Initiated | H.C. Wainwright | Buy |
View All
Cervomed Inc Stock (CRVO) Latest News
Price to earnings forward of CervoMed Inc. – FWB:DP8 - TradingView
Price to book forward of CervoMed Inc. – NASDAQ:CRVO - TradingView
Price to book forward of CervoMed Inc. – DUS:DP8 - TradingView
Price to sales forward of CervoMed Inc. – NASDAQ:CRVO - TradingView
Enterprise value to EBITDA forward of CervoMed Inc. – NASDAQ:CRVO - TradingView
Enterprise value to EBITDA forward of CervoMed Inc. – DUS:DP8 - TradingView
Enterprise value to revenue forward of CervoMed Inc. – DUS:DP8 - TradingView
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally - Stocktwits
CervoMed (CRVO) Schedule 13G: Manager-linked 750,000-share holding - Stock Titan
H.C. Wainwright Keeps Their Buy Rating on CervoMed (CRVO) - The Globe and Mail
CRVO stock rockets nearly 100% on patent win before offering news cools rally - MSN
CervoMed Inc. Actuals & Estimates (NASDAQ:CRVO) - TradingView
CRVO Forecast — Price Target — Prediction for 2027 - TradingView
Why did CRVO stock crash 22% in pre-market trading today? - MSN
CervoMed Inc (CRVO) Valuation: PE, PB & Fair Value Analysis - TradingKey
CervoMed Closes $10 Million Stock Offering - Moomoo
CervoMed closes $10 million registered direct offering By Investing.com - Investing.com Nigeria
CervoMed closes $10 million registered direct offering - Investing.com
CervoMed (NASDAQ: CRVO) closes $10M registered direct stock sale - Stock Titan
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - Moomoo
CervoMed Inc. Announces $10 Million Direct Offering of Common Stock and Placement Agent Warrants – June 2026 - Minichart
Form 424B5 CervoMed Inc For: 22 June By Investing.com - Investing.com Nigeria
CervoMed (NASDAQ: CRVO) seeks $10M via 2.5M-share offering; patent allowance noted - Stock Titan
CervoMed Announces $10 Million Registered Direct Offering; Engages H.C. Wainwright - TradingView
CervoMed shares surge after securing US patent protection for dementia therapy (CRVO) - MSN
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - The Manila Times
CRVO Stock Explodes As Insider Buying Fuels Biotech Momentum - timothysykes.com
CervoMed announces $10M registered direct offering priced at-the-market - TipRanks
CervoMed rises on patent news, pares gains after $10M equity sale - TechStock²
CervoMed Reports $10 Million Direct Offering of Shares - Moomoo
CervoMed prices $10M registered direct offering at $4/share By Investing.com - Investing.com India
CervoMed prices $10M registered direct offering at $4/share - Investing.com
CervoMed Announces $10 Million Registered Direct Offering - GlobeNewswire
CervoMed sells 2.5 million shares at $4.00 each to raise $10M - Stock Titan
CervoMed Inc. Receives Patent Allowance for Neflamapimod in Lewy Body Dementia, Securing IP Protection Through 2042 – Minichart - Minichart
CervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO) - Yahoo Finance
CRVO Stock Soars As Insider Buy And Cash Raise Extend Runway - StocksToTrade
CRVO Stock Explodes As Insider Buy Fuels Biotech Momentum - timothysykes.com
3 Stocks To Watch Today: CRVO, SPRO, QNRX - RTTNews
CervoMed stock jumps 20% on new U.S. patent allowance By Investing.com - Investing.com Nigeria
CervoMed stock jumps 20% on new U.S. patent allowance - Investing.com UK
Cervomed Inc Stock (CRVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cervomed Inc Stock (CRVO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Winton Matthew | Chief Commercial and Business |
Nov 17 '25 |
Buy |
8.43 |
3,500 |
29,505 |
13,500 |
| Winton Matthew | Chief Commercial and Business |
Nov 18 '25 |
Buy |
7.95 |
1,500 |
11,925 |
15,000 |
| Gregoire Sylvie | Director |
Nov 17 '25 |
Buy |
8.46 |
10,807 |
91,427 |
12,500 |
| Gregoire Sylvie | Director |
Nov 17 '25 |
Buy |
8.46 |
10,793 |
91,309 |
1,484,078 |
| ELDER WILLIAM ROBERT | CFO, GC & Secretary |
Nov 18 '25 |
Buy |
8.32 |
2,500 |
20,800 |
12,500 |
| ELDER WILLIAM ROBERT | CFO, GC & Secretary |
Nov 17 '25 |
Buy |
8.45 |
1,000 |
8,450 |
10,000 |
| ALAM JOHN J | CEO & President |
Nov 17 '25 |
Buy |
8.46 |
10,807 |
91,427 |
1,484,078 |
| ALAM JOHN J | CEO & President |
Nov 17 '25 |
Buy |
8.46 |
10,793 |
91,309 |
12,500 |
| Gregoire Sylvie | Director |
Nov 13 '25 |
Buy |
7.51 |
4,447 |
33,397 |
1,471,578 |
| Gregoire Sylvie | Director |
Nov 14 '25 |
Buy |
7.57 |
1,707 |
12,922 |
1,473,285 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):